DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
Enrique
Grande Pulido
Publications dans lesquelles il/elle collabore avec Enrique Grande Pulido (19)
2023
-
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
Prostate, Vol. 83, Núm. 4, pp. 376-384
-
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
European Journal of Cancer, Vol. 188, pp. 39-48
-
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 24, Núm. 11, pp. 1252-1265
2022
-
Corrigendum to “589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)”: [Annals of Oncology 32 suppl. 5 (2021) S637-S638] (Annals of Oncology (2021) 32 suppl. 5(S637-S638) (S0923753421033317), (10.1016/j.annonc.2021.08.1102))
Annals of Oncology
-
Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy
Journal of Clinical Medicine, Vol. 11, Núm. 3
-
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
ESMO Open, Vol. 7, Núm. 2
2021
2020
2017
-
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study
Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
-
Translational research in neuroendocrine tumors: Pitfalls and opportunities
Oncogene, Vol. 36, Núm. 14, pp. 1899-1907
2015
-
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis
BMC Cancer, Vol. 15, Núm. 1
-
Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors
Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 6, pp. 1099-1114
-
Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993
2014
2013
-
The targeted therapy revolution in neuroendocrine tumors: In search of biomarkers for patient selection and response evaluation
Cancer and Metastasis Reviews, Vol. 32, Núm. 3-4, pp. 465-477
2012
-
Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?
Cancer metastasis reviews, Vol. 31, Núm. 1-2, pp. 47-53
2011
-
Advances in pancreatic neuroendocrine tumor treatment: [3]
New England Journal of Medicine
2009
-
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
Annals of Oncology, Vol. 20, Núm. 11, pp. 1803-1812